The Valley Desk

Publications on Disease research from Merck & Co.

A filtered view. Show the full list.

Refine

53 publications · listings 1–24

Listings

  1. ArticleBioorganic & medicinal chemistry letters

    Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  2. ArticleJournal of medicinal chemistry

    Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven Malignancies

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  3. Clinical trial reportJournal of medicinal chemistry

    Discovery of MK-1088 as a Potent A2A/A2B Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  4. ArticleJournal of medicinal chemistry

    Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  5. ArticleACS infectious diseases

    Activity Refinement and Property Assessment of Peptidomimetics with Potent Antimalarial Activity That Target Plasmepsin V

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  6. ArticleACS infectious diseases

    Allosteric Crosstalk between Inhibitor Binding Sites Drives Enhanced Islatravir Susceptibility in F227C HIV-1 Reverse Transcriptase

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  7. ArticleACS medicinal chemistry letters

    Discovery of Potent 1,3-Cyclobutane-Containing Dual A2A/A2B Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  8. ArticleNature communications

    AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  9. ArticleNature medicine

    Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  10. ArticleScience (New York, N.Y.)

    Chemovaccination with a late-liver-stage antimalarial induces durable immunity against malaria

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  11. ArticlePLoS pathogens

    Dual plasmepsin IX and X inhibitors are refractory to development of resistance

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  12. ArticleFrontiers in oncology

    Multi-parameter optimization of a novel anti-TROP2 MMAE antibody-drug-conjugate for solid tumor therapy

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  13. ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    Neurofilament light chain in plasma as a sensitive diagnostic biomarker of peripheral neurotoxicity: In Vivo mouse studies with oxaliplatin and paclitaxel - NeuroDeRisk project

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  14. ArticleBioorganic & medicinal chemistry letters

    Discovery of arylsulfonamides as a novel class of allosteric integrase inhibitors with antiviral activity

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  15. ArticleBiotechnology reports (Amsterdam, Netherlands)

    Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor

    Verified Author affiliations on the Europe PMC record name GSK, Merck & Co. Affiliation source

    Disease researchAdded

  16. ArticleCell chemical biology

    High-resolution photocatalytic mapping of SARS-CoV-2 spike interactions on the cell surface

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  17. ArticleCell chemical biology

    Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  18. ArticleDiabetes research and clinical practice

    Serum adiponectin concentrations as a risk factor for cardiovascular complications in type 1 diabetes

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  19. ArticleiScience

    Distinct subsets of neutrophils crosstalk with cytokines and metabolites in patients with sepsis

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  20. ArticleJournal of medicinal chemistry

    Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  21. ArticleJournal of medicinal chemistry

    Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  22. ArticleACS medicinal chemistry letters

    Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  23. ArticleACS medicinal chemistry letters

    2-Aminopyridines as Potent and Selective Nav1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model

    Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

    Disease researchAdded

  24. ArticleACS medicinal chemistry letters

    Discovery of Broad-Spectrum Herpes Antiviral Oxazolidinone Amide Derivatives and Their Structure-Activity Relationships

    Verified Author affiliations on the Europe PMC record name GSK, Merck & Co. Affiliation source

    Disease researchAdded